Annovis Bio Inc. (ANVS) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Annovis Bio Inc. (NYSE: ANVS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.02 (0.00% 1D, market cap $43.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ANVS ranks #650 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANVS carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BMEA (Biomea Fusion Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $45.1M) and DWTX (Dogwood Therapeutics Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -32.3%, cap $41.8M). Among the 5-stock peer group, ANVS leads on earnings multiple (N/A) while GRCE leads on capital efficiency (-18.9% ROIC).
Per ANVS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001477845), Annovis Bio Inc. generated $0 in revenue, -$28.9M in net income, and -$25.6M in free cash flow against $21.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 51.7 (NEUTRAL RANGE)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While ANVS currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.26) and Max Pain ($1.07) forces dealer call-delta covering toward $5.78.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Annovis Bio Inc. (ANVS) slipped 0.00% to $1.02, trading at 2% of its 52-week range ($0.93 – $5.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
MALVERN, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neu
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as
Maria Maccecchini, PhD, CEO of Annovis, will join industry panel with pharma leaders and present company updatesMALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”),
MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neu
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ANVS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ANVS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Annovis Bio Inc. (ANVS) ranks #650 by composite RQD confidence (40/100, grade D-) and #767 by equity capitalization ($43.5M). Within this direct 5-issuer industry benchmark cohort, ANVS leads on earnings valuation at N/A trailing P/E, while GRCE leads on capital efficiency and profitability with -18.9% ROIC and — gross margin. ATHE currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with ANVS at 40/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ANVS
ACTIVE
Annovis Bio Inc. | D- | 40/100 | — | — | -35.0% | 0.00% | $43.5M | Benchmark Subject |
| BMEA Biomea Fusion Inc. | D- | 40/100 | — | — | -35.0% | -3.84% | $45.1M | /bmea-vs-anvs → |
| DWTX Dogwood Therapeutics Inc. | D- | 41/100 | — | — | -32.3% | -0.81% | $41.8M | /dwtx-vs-anvs → |
| GRCE Grace Therapeutics Inc. | D- | 35/100 | — | — | -18.9% | -3.48% | $40.8M | /grce-vs-anvs → |
| ATHE Alterity Therapeutics Limited | D+ | 58/100 | — | — | — | +2.93% | $40.7M | /athe-vs-anvs → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Annovis Bio Inc. (ANVS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$28.9M, operating cash flow of -$25.6M, and free cash flow of -$25.6M (-17.0% YoY). On the balance sheet, ANVS closed FY2025 with $21.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$28.9M | -$25.6M | -$25.6M | $21.1M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$24.6M | -$21.9M | -$21.9M | $13.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$56.2M | -$40.0M | -$40.0M | — | — |
As of 2026-11-01, Annovis Bio Inc. (NYSE: ANVS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.02 (0.00% 1D, market cap $43.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ANVS ranks #650 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANVS carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BMEA (Biomea Fusion Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $45.1M) and DWTX (Dogwood Therapeutics Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -32.3%, cap $41.8M). Among the 5-stock peer group, ANVS leads on earnings multiple (N/A) while GRCE leads on capital efficiency (-18.9% ROIC).
Per ANVS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001477845), Annovis Bio Inc. generated $0 in revenue, -$28.9M in net income, and -$25.6M in free cash flow against $21.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ANVS last traded at $1.02 (0.00% on volume of 1,482,588 shares), positioning the stock -19.05% below its 50-day simple moving average ($1.26) and -46.87% below its 200-day simple moving average ($1.92). Across its 52-week range of $0.93 to $5.50, ANVS sits at the 2.0% percentile with a 14-day RSI of 51.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.15).
Why ANVS Stock Traded Steady Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.